Ads
related to: carboplatin
Search results
Cullinan Therapeutics announces success for zipalertinib as combo therapy
Clinical Trials Arena via Yahoo Finance· 13 hours agoEGFR is overexpressed in tumour cells and involved in cell proliferation. Johnson & Johnson’s...
ASCO24: Akeso’s bispecific vvonescimab faces a rocky road ahead in NSCLC
Pharmaceutical Technology via Yahoo Finance· 2 days agoCompared to the chemotherapy control, ivonescimab plus...
EMA Panel Nods to Seven New Cancer Drugs
Medscape· 4 days agoThe drugs include an anti–PD-L1 monoclonal antibody, a biosimilar, and five generics, with indications covering a wide spectrum of cancers.
ASCO 2024: AbbVie flexes early success of ADC pipeline in solid tumours
Clinical Trials Arena via Yahoo Finance· 15 hours agoThe therapy was evaluated as a monotherapy and in combination with AbbVie’s investigative programmed...
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 5 hours agoLate-breaking results from PALOMA-2 study of subcutaneous amivantamab in combination with lazertinib show clinically meaningful antitumor response and improved safety profile in patients with ...
Carefully Designing De-escalation Trials in Breast Cancer
Medscape· 5 days agoDe-escalation trials in early breast cancer are "critical to preserving quality of life" but require...
Novel targeted cancer therapies demonstrate activity and safety in metastatic solid tumors
Medical Xpress· 4 hours agoThe studies were featured in an oral abstract session highlighting the development of new molecularly targeted agents. Preliminary data from a Phase I study evaluating the novel antibody-drug ...
Merck’s KEYTRUDA shows survival benefits in Phase III TNBC trial
Clinical Trials Arena via Yahoo Finance· 6 days agoParticipants were assigned in a 2:1 ratio to receive either KEYTRUDA with chemotherapy or a...
Cantargia ASCO Presentation Highlights Positive Clinical Data on Nadunolimab Counteracting...
Digital Journal· 1 day agoEarly efficacy data from the phase Ib/II trial TRIFOUR, NCT05181462 , also shows signs of promising efficacy in TNBC with a 60% response rate for nadunolimab combined with carboplatin ...
First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related...
Forrest City Times-Herald· 3 days agoJohnson & Johnson announced today first data from the Phase 3 PALOMA-3 study evaluating subcutaneous (SC) amivantamab combined with lazertinib in patients with locally advanced or metastatic ...
